Key regions: Germany, India, United Kingdom, China, Canada
The Oncology Drugs market in Asia is experiencing significant growth due to various factors.
Customer preferences: There is a growing demand for personalized medicine and targeted therapies in the Oncology Drugs market in Asia. Patients are seeking treatments that are tailored to their specific genetic makeup and medical history. Additionally, there is a preference for drugs that have fewer side effects and are more effective in treating cancer.
Trends in the market: Several Asian countries, such as China and Japan, are investing heavily in cancer research and development. This has led to the introduction of new and innovative Oncology Drugs that are more effective in treating cancer. Moreover, the increasing aging population in Asia has resulted in a higher incidence of cancer, leading to a rise in demand for Oncology Drugs. Another trend in the market is the increasing adoption of immunotherapy, which is a type of treatment that uses the body's immune system to fight cancer.
Local special circumstances: In China, the government has introduced a series of measures to encourage the development of the Oncology Drugs market. This includes fast-tracking the approval process for new drugs and providing subsidies for cancer treatment. In Japan, there is a focus on developing drugs that target specific genetic mutations in cancer cells. South Korea is also investing heavily in cancer research and development, with a particular focus on developing biosimilars, which are cheaper versions of biologic drugs.
Underlying macroeconomic factors: The Oncology Drugs market in Asia is being driven by several macroeconomic factors. The increasing incidence of cancer in the region is a major driver, as is the growing demand for personalized medicine. Additionally, the rising disposable income in many Asian countries has led to an increase in healthcare spending, which is driving growth in the Oncology Drugs market. Finally, the increasing investment in cancer research and development by governments and private companies is also contributing to the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
